Loading…
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $77M | $-33M | $-38M | $-30M | -60.1% | -3.1% | -25.4% |
| 2024 | $80M | $-46M | $-52M | $-23M | -58.8% | -1.5% | -7.3% |
| 2023 | $81M | $-49M | $-56M | $-48M | -46.2% | 13.6% | -35.6% |
| 2022 | $71M | $-81M | $-86M | $-77M | -53.9% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 71.33 | 81.06 | 79.87 | 77.36 |
| Operating Revenue | - | 71.33 | 81.06 | 79.87 | 77.36 |
| Cost Of Revenue | - | 12.36 | 11.88 | 11.58 | 10.70 |
| Gross Profit | - | 58.97 | 69.18 | 68.28 | 66.67 |
| Operating Expense | - | 142.92 | 126.45 | 118.82 | 103.76 |
| Research And Development | - | 22.86 | 17.56 | 17.99 | 14.61 |
| Selling General And Administration | - | 120.06 | 108.89 | 100.83 | 89.16 |
| Total Expenses | - | 155.28 | 138.33 | 130.40 | 114.46 |
| Operating Income | - | -83.95 | -57.27 | -50.53 | -37.10 |
| Total Operating Income As Reported | - | -83.95 | -57.27 | -50.53 | -37.10 |
| EBITDA | - | -81.02 | -49.42 | -45.90 | -32.79 |
| Normalized EBITDA | - | -81.02 | -56.70 | -49.85 | -36.76 |
| EBIT | - | -81.73 | -50.03 | -46.61 | -33.27 |
| Interest Income | 0 | - | - | - | - |
| Interest Expense | - | 4.47 | 5.41 | 4.66 | 5.14 |
| Net Interest Income | - | -4.47 | -5.41 | -4.66 | -5.14 |
| Other Non Operating Income Expenses | - | 2.22 | -0.04 | -0.03 | -0.15 |
| Other Income Expense | - | 2.22 | 7.24 | 3.92 | 3.82 |
| Interest Income Non Operating | 0 | - | - | - | - |
| Interest Expense Non Operating | - | 4.47 | 5.41 | 4.66 | 5.14 |
| Net Non Operating Interest Income Expense | - | -4.47 | -5.41 | -4.66 | -5.14 |
| Pretax Income | - | -86.20 | -55.44 | -51.27 | -38.42 |
| Tax Provision | - | 0.05 | 0.11 | 0.24 | 0.01 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0.83 | 0 |
| Net Income Continuous Operations | - | -86.24 | -55.55 | -51.51 | -38.43 |
| Net Income From Continuing And Discontinued Operation | - | -86.24 | -55.55 | -51.51 | -38.43 |
| Net Income From Continuing Operation Net Minority Interest | - | -86.24 | -55.55 | -51.51 | -38.43 |
| Net Income | - | -86.24 | -55.55 | -51.51 | -38.43 |
| Net Income Common Stockholders | - | -86.24 | -55.55 | -51.51 | -38.43 |
| Net Income Including Noncontrolling Interests | - | -86.24 | -55.55 | -51.51 | -38.43 |
| Normalized Income | - | -86.24 | -62.84 | -54.63 | -42.40 |
| Diluted NI Availto Com Stockholders | - | -86.24 | -55.55 | -51.51 | -38.43 |
| Basic Average Shares | 26.73 | 47.85 | 48.63 | 50.13 | - |
| Diluted Average Shares | 26.73 | 47.85 | 48.63 | 50.13 | - |
| Reconciled Depreciation | - | 0.71 | 0.61 | 0.71 | 0.49 |
| Reconciled Cost Of Revenue | - | 12.36 | 11.88 | 11.58 | 10.70 |
| Total Unusual Items | - | - | 7.29 | 3.96 | 3.97 |
| Total Unusual Items Excluding Goodwill | - | - | 7.29 | 3.96 | 3.97 |
| Special Income Charges | - | - | 0 | -1.96 | 0 |
| Other Special Charges | - | - | - | 1.96 | - |
| Gain On Sale Of Security | - | - | 7.29 | 5.92 | 3.97 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Sight Sciences, Inc.this co. | SGHT | $250M | -6.51 | 3.91 | -60.1% | -6.07 |
| Anavex Life Sciences Corp. | AVXL | $261M | -5.63 | 2.75 | -48.9% | - |
| Akebia Therapeutics, Inc. | AKBA | $260M | -48.70 | 7.98 | -16.4% | 5.86 |
| Fate Therapeutics, Inc. | FATE | $258M | -1.89 | 1.24 | -65.8% | -2.14 |
| Nuvectis Pharma, Inc. | NVCT | $257M |
| - |
| - |
| - |
| - |
| - |
| -9.70 |
| 13.93 |
| -143.6% |
| - |
| Codexis, Inc. | CDXS | $255M | -5.79 | 5.04 | -87.0% | -8.18 |
| Protara Therapeutics, Inc. | TARA | $248M | -4.32 | 1.26 | -29.2% | -3.14 |
| Coherus Oncology, Inc. | CHRS | $243M | 1.45 | 3.98 | 275.4% | -1.14 |
| Treace Medical Concepts, Inc. | TMCI | $239M | -4.06 | 2.74 | -67.6% | -6.98 |
| Peer Median | - | -4.98 | 3.37 | -57.3% | -2.64 | |